Filter By:

Identification of an orally bioavailable dual Cyclin-K glue degrader – CDK12/13 inhibitor’

  • CDK12/13
  • Clinical
  • 2021

Dec. 01, 2021

Edward K. Ainscow, Adrian Campbell, Michael Cripps, Robert Workman, Stuart Thomson, Kam Chohan, Samien Crepin, Mahiro Sunose, Jamie Patient, Jane Kendrew, Ash Bahl

Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype

  • CDK12/13
  • Clinical
  • 2020

Jun. 01, 2020

Edward K. Ainscow

Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer

  • CDK7
  • Clinical
  • 2021

Dec. 09, 2021

M.G. Krebs, S. Lord, L. Kenny, R.D. Baird, I. MacPherson, A. Bahl, G. Clack, E. Ainscow, A.G. Barrett, P. Dickinson, M.J. Fuchter, M. Lehnert, S. Ali, S. Mcintosh, R.S. Coombes

A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

  • CDK7
  • Clinical
  • 2021

Dec. 08, 2021

Sacha J Howell, Laura M Kenny, Simon Lord, Matthew G Krebs, Tobias Arkenau, Richard Baird, Iain R MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Athony GM Barrett, Paul A Dickinson, Matthew J Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh, Charles Coombes

Study of samuraciclib(CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer

  • CDK7
  • Clinical
  • 2021

Sep. 01, 2021

S.J. Howell, M.G. Krebs, S. Lord, L. Kenny, A. Bahl, G. Clack, E. Ainscow, H.I. Arkenau, J.L. Mansi, C. Palmieri, P. Richards, R. Jeselsohn, Z. Mitri, W.J. Gradishar, S. Sardesai, J. O'Shaughnessy, M. Lehnert, S. Ali, S. McIntosh, R.C. Coombes

The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

  • CDK7
  • Pre-clinical
  • 2022

Jun. 29, 2022

Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan

2.5 Angstrom – resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942

  • CDK7
  • Pre-clinical
  • 2021

Feb. 16, 2021

Basil J. Gerber, Johnathan Remis, Simak Ali, Eva Nogales

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment - supplementary files

  • CDK7
  • Pre-clinical
  • 2018

Mar. 01, 2018

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

  • CDK7
  • Pre-clinical
  • 2018

Mar. 01, 2018

Hetal Petal, Manikandan Periyasamy, Georgina P Sava, Alexander Bondke, Brian W. Slafer, Sebastian H B Kroll, Marion Barbazanges, Richard Starkey, Silvia Ottaviani, Alison Harrod, Eric O Adoagye, Laki Buluwela, Matthew J Fuchter, Anthony G M Barrett, R Charles Coombes, Simak Ali